 Connection
Jennifer Diamond to Protein Kinase Inhibitors
This is a "connection" page, showing publications Jennifer Diamond has written about Protein Kinase Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.854 |
|
|
|
-
Davis SL, Ionkina AA, Bagby SM, Orth JD, Gittleman B, Marcus JM, Lam ET, Corr BR, O'Bryant CL, Glode AE, Tan AC, Kim J, Tentler JJ, Capasso A, Lopez KL, Gustafson DL, Messersmith WA, Leong S, Eckhardt SG, Pitts TM, Diamond JR. Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors. Clin Cancer Res. 2020 09 01; 26(17):4633-4642.
Score: 0.477
-
Diamond JR, Eckhardt SG, Pitts TM, van Bokhoven A, Aisner D, Gustafson DL, Capasso A, Sams S, Kabos P, Zolman K, Colvin T, Elias AD, Storniolo AM, Schneider BP, Gao D, Tentler JJ, Borges VF, Miller KD. A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer. Breast Cancer Res. 2018 08 02; 20(1):82.
Score: 0.421
-
Owsley J, Jimeno A, Diamond JR. Palbociclib:CDK4/6 inhibition in the treatment of ER-positive breast cancer. Drugs Today (Barc). 2016 Feb; 52(2):119-29.
Score: 0.354
-
Diamond JR, Boni V, Lim E, Nowakowski G, Cordoba R, Morillo D, Valencia R, Genvresse I, Merz C, Boix O, Frigault MM, Greer JM, Hamdy AM, Huang X, Izumi R, Wong H, Moreno V. First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy. Clin Cancer Res. 2022 04 01; 28(7):1285-1293.
Score: 0.136
-
Weiss J, Afghahi A, Shagisultanova E, Diamond JR. Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast Cancer. Oncology (Williston Park). 2018 Oct 15; 32(10):513-5.
Score: 0.107
-
Capasso A, Pitts TM, Klauck PJ, Bagby SM, Westbrook L, Kaplan J, Soleimani M, Spreafico A, Tentler JJ, Diamond JR, Arcaroli JJ, Messersmith WA, Eckhardt SG, Leong S. Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models. Anticancer Drugs. 2018 10; 29(9):827-838.
Score: 0.106
-
Ryall KA, Kim J, Klauck PJ, Shin J, Yoo M, Ionkina A, Pitts TM, Tentler JJ, Diamond JR, Eckhardt SG, Heasley LE, Kang J, Tan AC. An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer. BMC Genomics. 2015; 16 Suppl 12:S2.
Score: 0.088
-
Tentler JJ, Ionkina AA, Tan AC, Newton TP, Pitts TM, Glogowska MJ, Kabos P, Sartorius CA, Sullivan KD, Espinosa JM, Eckhardt SG, Diamond JR. p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer. Mol Cancer Ther. 2015 May; 14(5):1117-29.
Score: 0.083
-
Tentler JJ, Bradshaw-Pierce EL, Serkova NJ, Hasebroock KM, Pitts TM, Diamond JR, Fletcher GC, Bray MR, Eckhardt SG. Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models. Clin Cancer Res. 2010 Jun 01; 16(11):2989-2998.
Score: 0.059
-
Pitts TM, Bradshaw-Pierce EL, Bagby SM, Hyatt SL, Selby HM, Spreafico A, Tentler JJ, McPhillips K, Klauck PJ, Capasso A, Diamond JR, Davis SL, Tan AC, Arcaroli JJ, Purkey A, Messersmith WA, Ecsedy JA, Eckhardt SG. Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer. Oncotarget. 2016 Aug 02; 7(31):50290-50301.
Score: 0.023
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|